Novo Nordisk A S (NVO)

Eli Lilly and Company (NYSE:LLY) cleared a notable regulatory hurdle on August 10, when Britain's drug regulator authorized the company's oral GLP-1 drug orforglipron, becoming the first country in Europe...

The ASML Holding NV ADRhedged™ (ASMH) carries a TipRanks Smart Score of 10 out of 10, the top of the scale, alongside a Strong Buy analyst consensu...

Shares of Danish pharmaceutical giant Novo Nordisk A/S (NYSE:NVO) experienced sharp volatility following its latest quarterly results.

Two healthcare players, Scholar Rock Holding Corporation (NASDAQ:SRRK) and Novo Nordisk A/S (NYSE:NVO), find their near-term narratives intertwined over manufacturing compliance.

The legal battle has erupted as competition between the companies intensifies.

Shares in Danish drugmaker Novo Nordisk ($NVO) fell about 2% to roughly $46 per share early Thursday. The decline came even though CEO Mike Doustar...

Shares of Hims & Hers Health ($HIMS), a U.S. telehealth firm, fell over 7% in premarket trading on Tuesday after reporting a more-than-expected Q2 ...

It is the first regulatory approval for the medication outside the U.S.

The duopoly dominating the multi-billion-dollar GLP-1 weight-loss market has moved from pharmacy shelves to the federal courtroom. Novo Nordisk A/S (NYSE:NVO) filed a lawsuit in U.S.